Triple-negative breast cancer recurrence after a mastectomy is one of the most aggressive types of cancer. It's harder to treat than other types of breast cancer because it lacks the three most ...

Patterns of distant recurrence were distinct. In women with triple-negative breast cancer the recurrence rate rose rapidly within the first 2 years after diagnosis, with a rapid decrease over the ...

those with triple-negative breast cancer had an increased likelihood of distant recurrence (hazard ratio, 2.6; 95% confidence interval, 2.0-3.5; P < 0.0001) and death (hazard ratio, 3.2 ...

The leading Triple Negative Breast Cancer Companies such as Shanghai Henlius Biotech, Jiangsu HengRui Medicine Co., Ltd., G1 ...

Triple-negative breast cancer (TNBC) has long been one of the most difficult forms of breast cancer to treat. Unlike other breast cancer subtypes, TNBC lacks ...

Nearly 75% of women treated with a novel vaccine designed to prevent triple-negative breast cancer achieved an immune ...

Atezolizumab (Tecentriq) plus chemotherapy after surgery did not improve survival in high-risk triple-negative breast cancer, ...

Triple-negative breast cancer lacks the expression of estrogen, progesterone and HER2 receptors, and so it makes it unresponsive for standard hormonal therapies targeting HER2.

During a Case-Based Roundtable event, Laura Huppert, MD, discussed data and considerations around using T-DXd in breast ...

Triple-negative breast cancer accounts for 10 percent to 20 percent of all new breast cancer cases, and is known for its high risk of recurrence and aggressive nature. Early recurrence is common ...

The efficacy of immunotherapy against triple-negative breast cancer (TNBC) heavily relies on intratumoral infiltration of cytotoxic T lymphocytes ...